Tashkin D P, Clements P J, Wright R S, Gong H, Simmons M S, Lachenbruch P A, Furst D E
Department of Medicine, UCLA School of Medicine 90024-1690.
Chest. 1994 Feb;105(2):489-95. doi: 10.1378/chest.105.2.489.
(1) To evaluate the relationship between the degree of pulmonary involvement by systemic sclerosis (SSc) and the degree of involvement of other organ systems by SSc at baseline. (2) To assess the degree of impairment in lung function at presentation and the annual rate of change in lung function to predict the rate of progression of involvement of extrapulmonary organ systems by SSc over time. (3) To determine whether survival in patients with SSc can be predicted from the degree of lung function impairment at baseline or from the annual rate of change in lung function.
Semiquantitative indices of pulmonary and extrapulmonary involvement and pulmonary function tests (PFTs) were analyzed and compared in 62 nonsmoking scleroderma patients enrolled in a 3-year prospective drug trial, vs 47 in a "study group" who underwent serial evaluation. The other 16 "early withdrawals" withdrew prior to the second evaluation. The indices of organ system involvement were based on clinical, physiologic, and biochemical findings as previously published. The PFTs included total lung capacity (TLC), forced vital capacity (FVC), FEV1, and single-breath diffusing capacity for carbon monoxide (Dsb). Annualized rates of change in PFTs and indices of extrapulmonary involvement were calculated for each subject from data collected on at least 2 separate occasions at least 6 months apart. Spearman rank correlations were performed between individual baseline PFTs (expressed as percent predicted) and (a) indices of extrapulmonary involvement at baseline, (b) annualized rates of change in PFTs, and (c) annualized rates of change in indices of extrapulmonary involvement. Correlations also were performed between the rate of change in each lung function measure and rates of change in indices of extrapulmonary involvement. The ability of PFTs at baseline and their rates of change to predict cumulative survival was assessed by Cox stepwise regression.
The degree of impairment in baseline PFTs was related to involvement of the right side of the heart but not to other extrapulmonary system involvement. Baseline PFTs were not related to the rate of subsequent decline of lung function or worsening of extrapulmonary organ system involvement. Subsequent annual rates of decline in lung function were related to worsening skin and upper gastrointestinal involvement. Cumulative survival may be related to the rate of decline in DCO, TLC, and FVC, but was not predicted by impairment in any measure of lung function.
With the exception of involvement of the right side of the heart consistent with cor pulmonale, the degree of pulmonary involvement by SSc was not correlated with the extent of extrapulmonary involvement. The degree of pulmonary involvement by SSc did not predict subsequent worsening of either pulmonary or extrapulmonary involvement. Worsening pulmonary involvement by SSc, in general, does not correlate with worsening involvement of extrapulmonary organ systems, except for the skin and upper gastrointestinal tract. A rapid decline in DCO or lung volumes may predict poor survival.
(1)评估系统性硬化症(SSc)患者肺部受累程度与基线时其他器官系统受累程度之间的关系。(2)评估就诊时肺功能损害程度及肺功能的年变化率,以预测SSc患者肺外器官系统随时间的受累进展速度。(3)确定能否根据基线时的肺功能损害程度或肺功能的年变化率预测SSc患者的生存率。
对62例参加为期3年的前瞻性药物试验的非吸烟硬皮病患者的肺和肺外受累半定量指标及肺功能测试(PFTs)进行分析和比较,另有47例在“研究组”中接受系列评估。其他16例“早期退出者”在第二次评估前退出。器官系统受累指标基于先前发表的临床、生理和生化检查结果。PFTs包括肺总量(TLC)、用力肺活量(FVC)、第1秒用力呼气容积(FEV1)和单次呼吸一氧化碳弥散量(Dsb)。根据至少间隔6个月的至少2次单独检查收集的数据,计算每个受试者PFTs和肺外受累指标的年化变化率。对个体基线PFTs(以预测值百分比表示)与(a)基线时肺外受累指标、(b)PFTs的年化变化率、(c)肺外受累指标的年化变化率进行Spearman等级相关性分析。还对每项肺功能指标的变化率与肺外受累指标的变化率进行相关性分析。通过Cox逐步回归评估基线时PFTs及其变化率预测累积生存率的能力。
基线PFTs的损害程度与右心受累有关,但与其他肺外系统受累无关。基线PFTs与随后的肺功能下降速度或肺外器官系统受累恶化无关。随后肺功能的年下降率与皮肤和上消化道受累恶化有关。累积生存率可能与一氧化碳弥散量(DCO)、TLC和FVC的下降率有关,但不能通过任何肺功能指标的损害来预测。
除与肺心病一致的右心受累外,SSc的肺部受累程度与肺外受累程度无关。SSc的肺部受累程度不能预测随后肺部或肺外受累的恶化。一般来说,SSc肺部受累的恶化与肺外器官系统受累的恶化无关,皮肤和上消化道除外。DCO或肺容积的快速下降可能预示生存率低。